<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115994</url>
  </required_header>
  <id_info>
    <org_study_id>AHPAP-MCE/death</org_study_id>
    <nct_id>NCT05115994</nct_id>
  </id_info>
  <brief_title>Antihypertensive and PAP Treatment in Obstructive Sleep Apnea Patients With Hypertension (AHPAP)</brief_title>
  <acronym>AHPAP</acronym>
  <official_title>Antihypertensive and PAP Treatment in Obstructive Sleep Apnea Patients With Hypertension -Long Term Prospective Analysis on Cardiovascular Events or Death (AHPAP-MCE/Death)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will perform a long term registry based prospective analysis on incidence&#xD;
      of major cardiovascular events or death in hypertensive patients with obstructive sleep apnea&#xD;
      .&#xD;
&#xD;
      Effects of PAP (positive airway pressure) compliance, antihypertensive medication and blood&#xD;
      pressure control will be investigated in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By using swedish personal ID numbers the investigators can combine data from several quality&#xD;
      registries in Sweden and will start with patients from a primary care registry (QregPV) that&#xD;
      had or received a hypertension diagnosis during the period 2008-2012. The investigators will&#xD;
      compare those who got an OSA diagnosis in the SESAR (Swedish sleep apnea registry) stratified&#xD;
      by high/low PAP compliance with an intraoral device group, a non treated OSA group as well as&#xD;
      a control group without OSA until 2021. Main outcome variables will be major cardiovascular&#xD;
      events or death. Outcome data will be collected from the National Patient Registry and Cause&#xD;
      of death registry.&#xD;
&#xD;
      Groups will be matched by propensity score for known confounders. Secondary analysis will&#xD;
      consider modifying effect of different antihypertensive drugs (the Swedish Prescribed Drug&#xD;
      Register, type of therapy; DDD comparison) and the actual degree of hypertension control&#xD;
      (blood pressure levels) on CV risk. It is intended to stratify the analysis for BP levels in&#xD;
      order to evaluate if lower BP targets further reduce CV risk in hypertensive OSA patients.&#xD;
      These analyses will likely be reported in separate publications.&#xD;
&#xD;
      HYPOTHESIS&#xD;
&#xD;
        1. PAP treatment in hypertensive OSA patients reduces the long term risk of major&#xD;
           cardiovascular events (MCE) and premature death. The risk reduction is modified by PAP&#xD;
           compliance, hypertension control and OSA severity.&#xD;
&#xD;
        2. In hypertensive OSA patients, the investigators previously identified betablockade as a&#xD;
           drug class leading to better pressure control (1). The investigators hypothesize that&#xD;
           any risk reduction by PAP treated OSA is influenced by the types of antihypertensive&#xD;
           drugs used.&#xD;
&#xD;
        3. Lower blood pressure targets (ie better BP control) may reduce the risk of&#xD;
           cardiovascular events in PAP treated OSA patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>14 Years</target_duration>
  <primary_outcome>
    <measure>Major cardiovascular event (MCE) or death</measure>
    <time_frame>First incidence during study, ie within 156 months (13 yrs) maximum</time_frame>
    <description>First incidence of new myocardial infarction, cardiac failure, stroke or death (cardiovascular and all)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure control</measure>
    <time_frame>at study end (latest available BP measurements up to december 2021), ie within 156 months (13 yrs) maximum</time_frame>
    <description>According to ESC/EHC 2018 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New incidence of atrial fibrillation</measure>
    <time_frame>First incidence during study, ie within 156 months (13yrs) maximum</time_frame>
    <description>New diagnosis from patient registry</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subanalysis of MCE/death incidence, stratified by blood pressure levels</measure>
    <time_frame>First incidence during study, ie within 156 months (13yrs) maximum</time_frame>
    <description>Does baseline and end of study BP levels influence our outcomes? Does lower BP targets further reduce the outcome risc?</description>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Hypertension</condition>
  <condition>Death, Cardiac</condition>
  <condition>Treatment Compliance</condition>
  <condition>Heart Failure</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Hypertensive OSA patients, high PAP compliance</arm_group_label>
    <description>Hypertensive OSA patients using their PAP device for at least 4 hrs/night</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertensive OSA patients, low PAP compliance</arm_group_label>
    <description>Hypertensive OSA patients using their PAP device for less than 4 hrs/night</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra oral device treatment</arm_group_label>
    <description>Hypertensive OSA patients treated with IOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated OSA hypertensive patients</arm_group_label>
    <description>Hypertensive OSA patients not using PAP or IOD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertensive patients without OSA</arm_group_label>
    <description>Control population from QregPV without OSA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continous positive airway pressure</intervention_name>
    <arm_group_label>Hypertensive OSA patients, high PAP compliance</arm_group_label>
    <arm_group_label>Hypertensive OSA patients, low PAP compliance</arm_group_label>
    <arm_group_label>Intra oral device treatment</arm_group_label>
    <other_name>Antihypertensive pharmacological treatment</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Propensity score matched registry cohorts&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All hypertensive and obstructive sleep apnea patients present in QregPV and SESAR&#xD;
             2008-2021.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients in the hypertensive control group (without OSA) will be excluded if they have&#xD;
             OSA diagnosis but are not present in the SESAR registry.&#xD;
&#xD;
          -  Subjects with missing data on any of the variables in the fitted model unless the&#xD;
             missing data can be accurately imputated.&#xD;
&#xD;
          -  Patients with low life expectancy (Age&gt;75 at study start, malignant disease).&#xD;
&#xD;
          -  Patients no longer living in VGR 2021.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Svedmyr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vastra Gotalands regionen, Sahlgrenska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <state>Västra Götaland</state>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Svedmyr S, Hedner J, Zou D, Parati G, Ryan S, Hein H, Pepin JL, Tkáčová R, Marrone O, Schiza S, Basoglu OK, Grote L; European Sleep Apnea Database (ESADA) study group. Superior hypertension control with betablockade in the European Sleep Apnea Database. J Hypertens. 2021 Feb 1;39(2):292-301. doi: 10.1097/HJH.0000000000002629.</citation>
    <PMID>33031170</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>November 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vastra Gotaland Region</investigator_affiliation>
    <investigator_full_name>Sven Svedmyr</investigator_full_name>
    <investigator_title>Principal investigator, MD Sahlgrenska University Hospital, PhD student Gothenburg University, Specialist internal medicine</investigator_title>
  </responsible_party>
  <keyword>Continous positive airway pressure</keyword>
  <keyword>Antihypertensive treatment</keyword>
  <keyword>Risc prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

